Provectus announced today that the organizing committee of the 6th Asia-Pacific Primary Liver Cancer Expert Meeting has accepted the Company's abstract "Phase 1 Study of PV-10 for Chemoablation of Hepatocellular Cancer and Cancer Metastatic to the Liver", for a poster presentation.
Provectus today announced that the presentation committee of the 5th European Post-Chicago Melanoma / Skin Cancer Meeting has accepted its abstract titled "Trials in Progress: Intralesional Rose Bengal vs Systemic Chemotherapy for Treatment of Locally Advanced Cutaneous Melanoma."
Provectus today announced that it had extended for an additional 60 days its Memorandum of Understanding with with Sinopharm-China State Institute of Pharmaceutical Industry ("Sinopharm-CSIPI"), the leader among all pharmaceutical research institutes in China, and Sinopharm A-THINK Pharmaceutical Co., Ltd. ("Sinopharm A-THINK"), the only injectable anti-tumor drug research and development, manufacture and distribution integrated platform within Sinopharm Group.
Provectus announced today that the abstract titled, "Phase 1 Study of PV-10 for Chemoablation of Hepatocellular Cancer and Cancer Metastatic to the Liver," to be presented at the European Society for Medical Oncology's 17th World Congress on Gastrointestinal Cancer, is scheduled for Thursday, July 2, 2015 from 10:30 to 11:00 a.m. and 4:55 to 5:25 p.m. local time. Sanjiv S. Agarwala, MD, of St. Luke's University Hospital and Health Network, Bethlehem, PA, will be the presenter.
Provectus provided the market with a business update in its quarterly investor conference call held on Thursday, May 7, 2015, that addresses several matters in conjunction with the filing of its Quarterly Report on Form 10-Q for the quarter ended March 31, 2015.
Provectus today announced its results of operations and financial condition for the first quarter ended March 31, 2015.
Provectus announced that it has received notification of allowance from the European Patent Office for its patent application protecting the synthetic process used to produce the small molecule Rose Bengal, the active pharmaceutical ingredient (API) in PV-10, the 'Company's lead oncology drug candidate. At the same time, the Japanese Patent Office has issued a patent for the same intellectual property.
Provectus announced today that the European Society for Medical Oncology (ESMO) has accepted the Company's abstract, "Phase 1 Study of PV-10 for Chemoablation of Hepatocellular Cancer and Cancer Metastatic to the Liver," for poster presentation at the ESMO 17th World Congress on Gastrointestinal Cancer.
Provectus announced today that it will hold its quarterly business update conference call at 4 pm Eastern Daylight Time, on Thursday, May 7, 2015.
Provectus announced today that it will present at the Asia Biotech Invest 2015 Conference, on Wednesday, May 20, 2015, at 10 am local time.
Provectus announced today that it has received from the US Patent and Trademark Office a Notice of Allowance for a joint patent application made with Pfizer, Inc. The patent will protect use of PV-10 in combination with certain other types of drugs in the treatment of melanoma and cancers of the liver.
Provectus enters phase 3 and has opened enrollment of patients for its phase 3 international FDA comparative clinical trial of PV-10 for melanoma.
Provectus announced today that it will present at the 7th Annual International Partnering Conference, ChinaBio Partnering Forum 2015, in Shanghai, China.
Provectus announced today that Dr. Sanjiv Agarwala will present data on PV-10, the Company's novel investigational drug for cancer, at the HemOnc Today Melanoma and Cutaneous Malignancies Annual Meeting on Friday, April 10, 2015 at the Sheraton New York Times Square Hotel.
Provectus announced today that it will present at the Growth Capital Expo at 1 pm PDT on Monday, April 13, 2015. The Expo is being held at Caesars Palace, April 12-14, 2015.
Provectus announced today that it will present at the 12th Annual BIO Asia International Conference, taking place on March 24th and 25th at the Grand Hyatt in Tokyo, Japan.
Provectus announced today that the amended protocol for its phase 3 study of PV-10 as a treatment for melanoma is now available at: http://clinicaltrials.gov/ct2/show/study/NCT02288897. The Company does not require additional review from the U.S. Food and Drug Administration(the "FDA") to start the phase 3 study, and has begun the process of gaining approval from the Institutional Review Board (IRB) of each individual site for the amended protocol.
Provectus today provides the market with a business update that addresses several matters.
Provectus announced today that it has received U.S. Patent No. 8,974,363 from the United States Patent and Trademark Office (USPTO).
Provectus today announced its results of operations and financial condition for the fourth quarter and year ended December 31, 2014.
(c) 2002-2015 Provectus Biopharmaceuticals, Inc.
All rights reserved.
Artwork designed by Tracy E. Miller.